Abstract: Method of inhibiting luteinising hormone secretion in a subject, said method comprising administering an optionally 5-alkyl- or -phenyl- and/or 2'-hydroxy-, -alkoxy- or -acyloxy-substituted 9,9-dimethyl-6,7-benzomorphan derivative having an oxygen containing substituent at the N-atom.

Abstract: The present invention provides compounds of formula I, ##STR1## wherein X is hydrogen, chlorine or bromine,R.sub.1 is methyl or ethyl,R.sub.2 is alkyl of 1 to 4 carbon atoms or allyl,R.sub.3 is CH.sub.2 CN or a group --NR.sub.4 R.sub.5, wherein R.sub.4 is hydrogen or alkyl of 1 to 4 carbon atoms, and R.sub.5 is alkanoyl of 1 to 5 carbon atoms, alkoxycarbonyl of 2 to 5 carbon atoms in the aggregate thereof, or mono-, di- or tri-haloalkoxycarbonyl of 3 to 5 carbon atoms, wherein the alkoxy group is substituted by halogen other than in the .alpha. position to the oxygen atom, or R.sub.5 is SO.sub.2 R.sub.6, wherein R.sub.6 is alkyl of 1 to 4 carbon atoms, mono-, di- or tri-haloalkyl of 1 to 4 carbon atoms, phenyl, phenyl mono-substituted by halogen or alkoxy of 1 to 4 carbon atoms, or pyridyl, or R.sub.6 is a group NR.sub.7 R.sub.8, wherein R.sub.7 and R.sub.8 are, independently, hydrogen or alkyl of 1 to 4 carbon atoms, or R.sub.7 and R.sub.8 together form --[CH.sub.2 ].sub.n -- or --[CH.sub.2 ].sub.2 --A--[CH.

Abstract: This invention provides new compounds of formula I, ##STR1## wherein X is hydrogen, chlorine or bromine,R.sub.1 is methyl or ethyl, andR.sub.2 is CH.sub.2 --CN, or a group NR.sub.3 R.sub.4, whereinR.sub.3 is hydrogen or alkyl of 1 to 4 carbon atoms, andR.sub.4 is SO.sub.2 R.sub.5, wherein R.sub.5 is alkyl of 1 to 4 carbon atoms, mono- to tri-halogenalkyl of 1 to 4 carbon atoms, phenyl, pyridyl, phenyl monosubstituted by halogen or alkoxy of 1 to 4 carbon atoms, or a group NR.sub.6 R.sub.7, wherein each ofR.sub.6 and R.sub.7 is independently hydrogen or alkyl of 1 to 4 carbon atoms, orR.sub.6 and R.sub.7 together are one of the groups (CH.sub.2).sub.n or (CH.sub.2).sub.2 --A--(CH.sub.2).sub.2, whereinn is a number from 3 to 7, andA is oxygen, sulphur or nitrogen substituted by alkyl of 1 to 4 carbon atoms or phenyl,useful as prolactin secretion agents and antiparkinson agents.

Abstract: This disclosure describes compounds of the formula ##STR1## wherein R.sub.1 represents hydrogen, fluoro, chloro, lower alkyl having 1 to 4 carbon atoms, or lower alkoxy having 1 to 4 carbon atoms, andR.sub.2 represents lower alkyl or ##STR2## where R.sub.5 represents hydrogen, fluoro, chloro, lower alkyl or lower alkoxy, andR.sub.3 and R.sub.4 each independently represent lower alkyl as defined above, andR.sub.3 and R.sub.4 together with N represent ##STR3## or pharmaceutically acceptable acid addition salts thereof, which are useful as anti-diabetic agents.

Abstract: This disclosure describes compounds of the formula ##STR1## where R.sub.1 represents hydrogen, fluoro, chloro, lower alkyl having 1 to 4 carbon atoms or lower alkoxy having 1 to 4 carbon atoms, andR.sub.2 represents hydroxy, andR.sub.3 and R.sub.4 each independently represent lower alkyl as defined above, orR.sub.3 and R.sub.4 together with N represent ##STR2## wherein n is 1, 2 or 3, andR.sub.5 and R.sub.6 each independently represent hydrogen or lower alkyl as defined above,or a pharmaceutically acceptable acid addition salt thereof, which are useful as anti-diabetic agents, in particular as hypoglycemic agents and inhibiting or impeding post-prandial hyperglycemia.

Abstract: This disclosure describes compounds of the formula ##STR1## where R.sub.1 represents hydrogen, fluoro, chloro, lower alkyl having 1 to 4 carbon atoms or lower alkoxy having 1 to 4 carbon atoms, andR.sub.2 and R.sub.3 each independently represent lower alkyl as defined above, orR.sub.2 and R.sub.3 together with N represent ##STR2## wherein n is 1, 2 or 3, andR.sub.4 and R.sub.5 each independently represent hydrogen or lower alkyl as defined above,or a pharmaceutically acceptable acid addition salt thereof, which are useful as anti-diabetic agents in particular as hypoglycemic agents and inhibiting or impeding post-prandial hyperglycemia.

Abstract: The present invention relates to a compound of formula I, ##STR1## wherein A is straight chain alkylene of 2 to 4 carbon atoms, or straight chain alkenylene of 2 to 4 carbon atoms,n is 1, 2 or 3,R is hydrogen or halogen of atomic number from 9 to 35, andeither (i) R.sub.1 is a group of formula II, ##STR2## wherein R.sub.2 and R.sub.3, independently, are hydrogen or alkyl of 1 to 4 carbon atoms, andR.sub.4 is alkyl of 1 to 4 carbon atoms, alkoxyalkyl of 2 to 5 carbon atoms, alkylthioalkyl of 2 to 5 carbon atoms, phenylalkyl or phenoxyalkyl or phenylthioalkyl, wherein the alkyl moiety has from 1 to 3 carbon atoms, or phenyl, the phenyl ring of each of the last four radicals being unsubstituted or mono-substituted by, or disubstituted independently by, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, hydroxy or halogen of atomic number from 9 to 35, andR.sub.5 is hydrogen,or (ii) R.sub.1 and R.sub.

Abstract: Ergots are described which are useful in the treatment of minimal brain dysfunction in children. A particularly useful compound is co-dergocrine.

Abstract: The present invention provides tetraline derivatives, useful for the treatment of hypertension, a process for their preparation and compositions containing these compounds.

Abstract: The present invention relates to cyclosporin derivatives, especially compounds of formula I ##STR1## wherein A is ##STR2## useful as anti-arthritic agents.

Abstract: Compounds of formula I ##STR1## selected from the group consisting of cyclosporin G, wherein A is ##STR2## dihydrocyclosporin G, wherein A is ##STR3## and isocyclosporin G, wherein A is ##STR4## are useful in treating inflammations and arthritis and as immuno-suppressant agents.

Abstract: Cinnamylalkyl-1-naphthylmethylamines, useful as antimycotic agents, and processes for their production.

Abstract: This invention relates to new pleuromutilins of the formula: ##STR1## wherein either R.sub.1 is ethyl or vinyl,n is an integer from 2 to 5,x is sulphur,a group ##STR2## or a group .dbd.N--R.sub.4 .sup.I, wherein eitherY and Z are both sulphur, orone of Y and Z is oxygen and the other is sulphur, andR.sub.4.sup.I is hydrogen or a group of the formula: ##STR3## wherein R.sub.1 is as defined above, each of R.sub.2 and R.sub.3 is alkyl of 1 to 10 carbon atoms, orR.sub.2 and R.sub.3 together with the nitrogen atom form a heterocycle of 5 to 7 ring members containing one nitrogen atom or one nitrogen atom and a further hetero member selected from sulphur, oxygen and a group .dbd.N--R.sub.5.sup.I,wherein R.sub.5.sup.I is alkyl of 1 to 5 carbon atoms or hydroxyalkyl of 1 to 4 carbon atoms, orR.sub.2 and R.sub.3 together with the nitrogen atom form a piperazinyl radical, the second nitrogen atom of which is substituted by a radical R.sub.5.sup.II,whereby R.sub.5.sup.

Abstract: 6-methyl-8.beta.-(2-pyridylthiomethyl)ergolene is useful in treating senile cerebral insufficiency and bladder incontinence.

Abstract: This invention provides new compounds of formula I, ##STR1## wherein R.sub.1 is amino, or ##STR2## wherein each of R.sub.3 and R.sub.4 is independently alkyl of 1 to 4 carbon atoms,R.sub.2 is alkyl of 1 to 4 carbon atoms or phenyl,R.sub.8 is hydrogen or alkyl of 1 to 4 carbon atoms, andA is --(CH.sub.2).sub.n --,wherein n is an integer from 1 to 3, with the proviso that when R.sub.1 is amino, R.sub.2 is methyl or phenyl and R.sub.8 is hydrogen,n is 2 or 3,or .dbd.N--CO--R.sub.5,wherein R.sub.5 is alkyl of 1 to 6 carbon atoms, alkenyl of 3 to 6 carbon atoms, a --(CH.sub.2).sub.m --R.sub.6 group,whereinm is an integer from 0 to 2, andR.sub.6 is phenyl, or phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms or alkylmercapto of 1 to 4 carbon atoms,or an --OR.sub.7 group,wherein R.sub.

Abstract: The invention provides polypeptides of formula I,A-B-Gly-D-E Iwherein A is Tyr or substituted Tyr,B is -Gly- or -(D)Ala-,D is, for example, Phe or MePhe andE is, for example, -Met-X, -Leu-X, -Nle-X, -Nva-X, -Ile-X, methioninesulhoxide-X, methioninesulphone-X wherein X is --NR'R" or --OR'" and each of R', R" and R'" independently signifies hydrogen or alkyl of 1 to 5 carbon atoms,which compounds possess pharmacological activity, for example, analgesic activity.

Abstract: Compounds of formula I ##STR1## wherein R.sub.1 is alkyl of 1 to 4 carbon atoms or benzyl,R.sub.2 is alkyl of 1 to 4 carbon atoms, andeither(i) A is .CH.sub.2.CH.sub.2.COOH; .CH.sub.2.CH(OH).COOH or .CH(OH).CH.sub.2.COOH and B is hydrogen, or (ii) A and B together are .CH.sub.2.CH(OH).CH.sub.2.; CH.sub.2.CH.sub.2.CH(OH); .CH.sub.2.CH(OH).CH(OH). or .CH(OH).CH.sub.2.CH(OH). are useful cerebral insufficiency agents.

Abstract: The present invention provides compounds of formula I, ##STR1## wherein X is hydrogen, chlorine or bromine andY is hydrogen or bromine, with the proviso that when X is chlorine Y is hydrogen,Z is carbonyl or sulphonyl,R.sub.1 is alkyl of 1 to 4 carbon atoms, andeither (i)R.sub.2 is hydrogen or alkyl of 1 to 5 carbon atoms, andR.sub.3 is hydrogen, alkyl of 1 to 5 carbon atoms, or phenyl,or (ii)R.sub.2 together with R.sub.3 is a radical of formula ##STR2## wherein R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are, independently, hydrogen or alkyl of 1 to 4 carbon atoms,or (iii)R.sub.2 together with R.sub.4 is a radical of formula--(CH.sub.2).sub.2 --A--(CH.sub.2).sub.2 --wherein A is a bond, oxygen, sulphur or NR.sub.8 wherein R.sub.8 is hydrogen, alkyl of 1 to 4 carbon atoms, phenyl or alkoxyphenyl,useful as venotonising agents.

Abstract: The invention provides polypeptides of the formula,A-B-Gly-D-E-FwhereinA is Tyr or substituted Tyr,B is, for example, -Gly-, -(D)-Ala-, or -(D)-Met-,D is Phe or substituted Phe,E is, for example, -Leu-, -Nle-, -Nva-, -Ile- or -Val-,and F is -NR.sub.7 CHR.sub.8 CH.sub.2 OR.sub.3 ',wherein, for example, R.sub.3 ' may be hydrogen or alkyl--CO--, R.sub.7 is hydrogen or alkyl and R.sub.8 is alkyl,which compounds possess pharmacological activity, for example, analgesic activity.

Abstract: Alpha-blocking agents, especially 9,10-dihydroergot-peptide alkaloids, are anti-obesity agents.